- ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to learn how safe KER-0193 is, the activity of KER-0193 in the body over a period of time, and the effect of KER-0193 to the body in adult healthy people taking single and multiple doses by the mouth that are increased a little at a time
This study is looking at a new medicine called KER-0193 for Fragile X syndrome. It aims to find out how safe the medicine is and what it does in healthy adults when taken by mouth, starting with small doses and increasing them gradually.
Belgium - active not recruitingPHASE2, PHASE3
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
This study is looking at the long-term safety of a cannabidiol gel (ZYN002) for children and teenagers with Fragile X Syndrome. Participants previously took part in other ZYN002 studies. The gel is applied to the skin twice a day for at least a year.
United States · Australia · New Zealand - authorisedTherapeutic exploratory (Phase II)
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants with Fragile X Syndrome
This study is testing a new medicine, MRM-3379, for men with Fragile X Syndrome. Researchers want to see if it's safe and if it helps with thinking and learning abilities. Some men will also receive a dummy pill.
Spain - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
Safety and tolerability of CTH120, first-in-human phase I study encompassing three parts: Single and Multiple Ascending doses and potential Food Interaction
This early-stage study is testing a new medicine called CTH120 for people with Fragile X syndrome. It's looking at how safe the medicine is, how well people can cope with different doses, and if food affects it. This is the first time it will be given to humans.
Spain